Healthcare / BiotechnologyHelsinki
$1.09
-0.00 (-0.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-20.0M · quality 82.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$93M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-41.8%
↓Gross Margin
85.8%
↑Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.6%
FCF CAGR
—
FCF margin
-530.2%
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.5M · net income $-17.9M · FCF $-18.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.5M | $3.5M | $2.8M | $2.6M | $3.5M |
| Net Income | $-17.9M | $-17.9M | $-23.4M | $-20.8M | $-22.1M |
| EBITDA | $-14.6M | $-14.6M | $-20.2M | $-17.8M | $-19.5M |
| EPS | -0.21 | -0.21 | -0.28 | -0.26 | -0.29 |
| Gross Margin | 85.8% | 85.8% | 80.1% | 66.9% | 90.2% |
| Operating Margin | -585.1% | -585.1% | -870.8% | -875.7% | -613.9% |
| Net Margin | -504.7% | -504.7% | -843.3% | -808.7% | -633.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.09 | 0.09 | 0.08 |
| Current Ratio | 4.01 | 4.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-18.8M | $-18.8M | $-20.0M | $-21.8M | $-29.2M |
| Returns | |||||
| ROE | -41.8% | -41.8% | -39.0% | -31.0% | -25.3% |
| Valuation | |||||
| P/B | 2.18 | 2.18 | 1.97 | 1.91 | 2.77 |
| Growth & Yield | |||||
| Revenue Growth | 27.6% | 27.6% | 8.2% | -26.4% | — |
| EPS Growth | 25.0% | 25.0% | -7.7% | 10.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.28 → -0.21
Residual
+21.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.